vadimezan has been researched along with paclitaxel in 9 studies
| Studies (vadimezan) | Trials (vadimezan) | Recent Studies (post-2010) (vadimezan) | Studies (paclitaxel) | Trials (paclitaxel) | Recent Studies (post-2010) (paclitaxel) |
|---|---|---|---|---|---|
| 272 | 16 | 101 | 31,874 | 5,729 | 15,395 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Henricson, BE; Li, ZY; Manthey, CL; Perera, PY; Vogel, SN | 1 |
| Lee, AE; McKeage, MJ; Pruijn, FB; Shalal-Zwain, S; Siim, BG; Wilson, WR | 1 |
| Chouaid, C; Freitag, L; Gibbs, D; Jameson, MB; Lafitte, JJ; Mainwaring, PN; McKeage, MJ; Quoix, E; Reck, M; Rosenthal, MA; Serke, M; Sullivan, R; Von Pawel, J | 1 |
| Freitag, L; Gibbs, D; Jameson, MB; Mainwaring, PN; McKeage, MJ; Reck, M; Rosenthal, MA; Sullivan, R; Von Pawel, J | 1 |
| Hida, T; Hirashima, T; Horai, T; Horio, Y; Kobayashi, K; Nishio, M; Shi, MM; Tamiya, M; Tanii, H; Yamamoto, N | 1 |
| Albert, I; Douillard, JY; Fan, X; Fandi, A; Heo, DS; Lara, PN; Losonczy, G; McKeage, MJ; Nakagawa, K; Reck, M; Scagliotti, G; von Pawel, J | 1 |
| Cathomas, R; Erdmann, A; Früh, M; Fustier, P; Krasniqi, F; Küttel, E; Mamot, C; Pless, M; Rauch, D; Siano, M; Simcock, M; Tscherry, G; Zippelius, A | 1 |
| Behe, M; Braun, F; Grosu, AL; Milanović, D; Niedermann, G; Weber, W | 1 |
| Bertherat, J; Beuschlein, F; Frantsev, R; Hantel, C; Jäckel, C; Lira, R; Mussack, T; Ozimek, A; Ragazzon, B; Reincke, M | 1 |
5 trial(s) available for vadimezan and paclitaxel
| Article | Year |
|---|---|
Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Treatment Outcome; Xanthones | 2008 |
Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Xanthones | 2009 |
Phase I study of intravenous ASA404 (vadimezan) administered in combination with paclitaxel and carboplatin in Japanese patients with non-small cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Asian People; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Remission Induction; Survival Rate; Tissue Distribution; Treatment Outcome; Xanthones | 2011 |
Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Odds Ratio; Paclitaxel; Quality of Life; Surveys and Questionnaires; Treatment Failure; Xanthones | 2011 |
Carboplatin and paclitaxel plus ASA404 as first-line chemotherapy for extensive-stage small-cell lung cancer: a multicenter single arm phase II trial (SAKK 15/08).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Small Cell Lung Carcinoma; Treatment Outcome; Xanthones | 2013 |
4 other study(ies) available for vadimezan and paclitaxel
| Article | Year |
|---|---|
Dissection of LPS-induced signaling pathways in murine macrophages using LPS analogs, LPS mimetics, and agents unrelated to LPS.
Topics: Animals; Antibodies, Monoclonal; Gene Expression Regulation; In Vitro Techniques; Lipid A; Lipopolysaccharide Receptors; Lipopolysaccharides; Macrophages; Mice; Mice, Inbred C3H; Paclitaxel; Phosphoproteins; Signal Transduction; Xanthenes; Xanthones | 1995 |
Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bibenzyls; Carboplatin; Dose-Response Relationship, Drug; Drug Synergism; Female; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Paclitaxel; Stilbenes; Time Factors; Xanthenes; Xanthones | 2003 |
The influence of the combined treatment with Vadimezan (ASA404) and taxol on the growth of U251 glioblastoma xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Cell Line, Tumor; Female; Fluorodeoxyglucose F18; Glioblastoma; Humans; Mice; Mice, Nude; Paclitaxel; Positron-Emission Tomography; Tumor Burden; Xanthones; Xenograft Model Antitumor Assays | 2012 |
TNF alpha signaling is associated with therapeutic responsiveness to vascular disrupting agents in endocrine tumors.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Angiogenesis Inhibitors; Animals; Cell Line, Tumor; DNA-Binding Proteins; Female; Humans; Interleukin-1 Receptor-Associated Kinases; Intracellular Signaling Peptides and Proteins; Kaplan-Meier Estimate; Mice, Nude; Nuclear Proteins; Paclitaxel; Proportional Hazards Models; Signal Transduction; Transcriptional Activation; Tumor Necrosis Factor alpha-Induced Protein 3; Tumor Necrosis Factor-alpha; Xanthones; Xenograft Model Antitumor Assays | 2016 |